高迁移率族蛋白1与卵巢上皮性癌患者预后及化疗敏感性的关系  

The prognostic and chemosensitive value of HMGB1 in epithelial ovarian cancer patients

作　　者：肖会廷[1] 张文琪[1] 刘文欣[1] 战忠利[2] 王珂[1] 郝权[1] 

机构地区：[1]天津医科大学肿瘤医院妇科肿瘤科国家肿瘤临床医学研究中心天津市"肿瘤防治"重点实验室,天津300060 [2]天津医科大学肿瘤医院病理科国家肿瘤临床医学研究中心天津市"肿瘤防治"重点实验室,天津300060

出　　处：《现代妇产科进展》2014年第10期783-786,共4页Progress in Obstetrics and Gynecology

摘　　要：目的:探讨高迁移率族蛋白1(HMGB1)在卵巢上皮性癌组织中的表达及其与卵巢癌临床病理特征、预后和化疗敏感性之间的相关性。方法:回顾分析2007年1月至2008年12月天津医科大学肿瘤医院妇科肿瘤科收治的55例卵巢癌患者的临床病理资料,以同期因子宫肌瘤行全子宫切除+附件切除术患者(18例)的正常卵巢组织标本为对照。采用免疫组化法检测HMGB1蛋白在卵巢癌组织和正常卵巢组织中的表达。比较卵巢癌组织中HMGB1表达水平与化疗敏感性的相关性,采用Kaplan-Meier法、Log-rank单因素分析和Cox回归模型多因素分析法计算生存率和预后相关因素。结果:卵巢癌组织中HMGB1蛋白的高表达率为58.18%,与正常卵巢组织(11.11%)比较,差异有统计学意义(P<0.05);卵巢癌组织中HMGB1蛋白表达水平与手术病理分期(P<0.01)、淋巴结转移(P<0.01)及有无原发耐药(P<0.05)密切相关。Kaplan-Meier生存分析显示,HMGB1高表达组和低表达组患者的5年总生存率分别为12.5%和64.5%,差异有统计学意义(P<0.01)。多因素Cox比例风险回归模型分析显示,HMGBl蛋白表达水平和肿瘤分期为影响卵巢癌患者预后的独立危险因素。结论:HMGBl蛋白高表达与卵巢癌患者的预后及化疗敏感性相关。HMGBl可能有望成为预测卵巢癌患者预后及化疗敏感性的分子标记物。Objective：To evaluate the expression of HMGB1 protein in specimens of human epithelial ovarian cancer （EOC） and it＇s significance in clinicopathological features,prognosis and chemosensitivity. Methods：From Jan.2007 to Dec.2008 in Tianjin Cancer Hospital,clinical data of 55 patients with ovarian cancer were retrospectively analyzed,and being compared with 18 control cases taken from the patients with normal ovary tissues. The expression of HMGB1 was determined by immunohistochemical staining. We evaluated the relationship between expression of HMGB1 and various clinicopathological factors. Results：The overexpression rate of HMGB1 in 55 ovary cancer tissues was 58.18%,which was significantly higher than those in the normal tissues（11. 11%,P〈0.05）. Overexpression HMGB1 were significantly associated with surgical-pathologic staging （P〈0.01）,lymph node metastasis （P〈0.01） and primary chemoresistance （P〈0.05）. Kaplan-Meier a-nalysis show that 5 year survival rate in the low expression group was 64.5%,which was significant higher than those in the high expression group （P〈0.01）. Multivariate analysis revealed that expres-sion of HMGB1 and tumor stage was independent prognositic factor of poor survival. Conclusions：HMGBl protein overexpression is associated with a poorer prognosis and primary chemoresistance in patients. HMGB1 may play a critical role in the initiation,progression,prognosis and chemosensitivi-ty of ovarian cancer. HMGBl may become a valuable marker for the prediction of prognosis and che-moresistance in patients with EOC.

关 键 词：卵巢癌 HMGB1 蛋白 预后 化疗敏感性 

分 类 号：R737.31[医药卫生—肿瘤]